Fluorescent Immunoassay PLGF And SFLT-1 POCT Kit

Intended use

This Fluorescent Immunoassay PLGF and sFLT-1 POCT Kit is designed for in vitro quantitative detection of PLGF and sFLT-1 in whole blood ,serum and plasma samples. It’s for professional only.

Summary

Soluble fms-like tyrosine kinase-1 (sFlt-1) is a truncated tyrosine kinase form that disables proteins with antiangiogenic properties and a shortened non-membrane splice variant of VEGFreceptor 1 (Flt-1) that signals angiogenesis. It contains an extracellular domain identical to that of Flt-1, but lacks both the transmembrane and intercellular domains present in Flt-1.Instead, sFlt-1 contains a novel 31 amino acid C-terminal sequence and 6 immunoglobulin-

like domains, with a binding site for VEGF and PIGF within the second domain from the N-terminus,resulting that sFlt-1 competes with Flt-1 to bind VEGF and PIGF, which effectively reducing serum concentrations of these two angiogenic growth factors.

PlGF is a protein highly expressed by the placenta with vasculogenic and angiogenic properties, which has a central role in spiral artery remodeling and the development of a low-resistance placental capillary network. Increased rates of preterm birth Low PIGF levels in high-risk pregnant women between 20° and 36 weeks of gestation is associated with increased risk of early-onset pre-eclampsia Increased risk of stillbirth characterized by severe placental vascular disease.

Principle

The fluorescent immunoassay PLGF and sFLT-1 POCT kit adopts microfluidic fluorescence immunoluminescence method, which helps get accurate PLGF and sFLT-1 level results in 10 minutes.

Why Test sFLT-1 and PLGF?

Pre-eclampsia (PE) is a complex multisystem disease of pregnancy globally responsible fora significant burden of maternal,perinatal,fetal morbidity and mortality. The current diagn-ostic criteria for preeclampsia include new onset of hypertension after 20 weeks’ gestatio-n coupled proteinuria, renal insuffciency, impaired liver function, neu-rologic complications,thrombocytopenia, or uteroplacental dysfunction,which have limited clinical value for prediction of preeclampsia and fetal adverse outcomes as the clinical presentation of preeclampsia is extremely variable, impacting the specifcity and reliability of clinical assessments for the prediction of preeclampsia.

More recently, the ISSHP, NICE and German (AWMF) guidelineshave included angiogenic testing as part of PE diagnosis. The sFlt-1/PlGF ratio is recommended for use in conjunctio with clinical information in triaging (rule-out and rule-in) women suspected to have PE.

Benefits

· Rapid reaction time of 10 minutes

· Multiple blood samples to choose

In the blood test of sFlt-1/PlGF,whole blood,serum,plasma are available to test with the Fluorescent Immunoassay PLGF and sFLT-1 POCT Kit.

· Get 3 results at a time

This Fluorescent Immunoassay PLGF and sFLT-1 POCT Kit detects the levles of PLGF and sFLT-1 ,and calculates the sFlT-1/PlGF ratio on LYOFIA ® platform.

A ratio of ≤38 had a negative predictive value of 98.9% for ruling out fetal adverse outcomes within 1 week, and a ratio of >38 had a positive predictive value of 53.5%or ruling in fetal adverse outcomes within 4 weeks. The sFlt-1/PlGF ratio cutoff of 38 demonstrated clinical value for the short-term prediction of preeclampsia in pregnancy women with suspected preeclampsia.

Hot Tags: fluorescent immunoassay plgf and sflt-1 poct kit, China, suppliers, manufacturers, factory, pricelist, quotation